BioNTech
safety trial in patients with malignant solid tumors who are not bot | BioNTech
Company
Deck Type
Sector
Industry
Deck date
November 2020
Slide
15 of 25
Related slides by other companies
Sigilon Therapeutics
Investor Presentation
October 2022
hem a phase safety and dose ranging study update | Sigilon Therapeutics
BenevolentAI
Investor Presentation
September 2024
ben phase | BenevolentAI
BenevolentAI
Results
March 2024
ben nearing completion of phase topline data expected end | BenevolentAI
Ocuphire Pharma
Investor Day
January 2022
safety summary from phase and phase studies way | Ocuphire Pharma
Other recent decks by BioNTech
See all presentations (12 decks)
Investor Presentation
August 2022
Results
August 2022
Investor Day
June 2022
Results
March 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights